 | Up a level |
2020
Vansteenkiste, J. F., Smit, E. F., Groen, H. J. M., Garon, E. B., Heist, R. S., Hida, T., Nishio, M., Kokowski, K., Grohe, C., Reguart, N., Mansfield, A. S., Robeva, A., Ghebremariam, S., Waldron-Lynch, M., Akimov, M., Nwana, N., Giovannini, M. and Wolf, J. (2020). Capmatinib in patients with METex14-mutated advanced non-small cell lung cancer who received prior immunotherapy: The phase II GEOMETRY mono-1 study. Ann. Oncol., 31. S. S830 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Wolf, J., Seto, T., Han, J. Y., Reguart, N., Garon, E. B., Groen, H. J., Tan, D. S. W., Hida, T., de Jonge, M., Orlov, S., V, Smit, E. F., Souquet, P., Vansteenkiste, J., Le Mouhaer, S., Robeva, A., Waldron-Lynch, M., Balbin, A., Fairchild, L., Giovannini, M. and Heist, R. S. (2020). Capmatinib (INC280) in patients (pts) with METex14-mutated advances NSCLC: an update from phase 2 GEOMETRY mono-1 study. Pneumologie, 74. S. S134 - 1. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1438-8790
2018
Tan, D. S., Kim, S-W., Sequist, L. V., Ponce Aix, S., Smit, E. F., Hida, T., Yang, J. C-H., Felip, E., Seto, T., Grohe, C., Wolf, J., Ko, J., Marriere, E., Belli, R., Giovannini, M. and Kim, D-W. (2018). Phase II results for single-agent nazartinib (EGF816) in adult patients (pts) with treatment-naive EGFR-mutant non-small cell lung cancer (NSCLC). Ann. Oncol., 29. S. 748 - 749. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Wolf, J., Seto, T., Han, J-Y., Reguart, N., Garon, E. B., Groen, H. J. M., Tan, D. S., Hida, T., de Jonge, M. J. A., Orlov, S. V., Smit, E. F., Souquet, P-J., Vansteenkiste, J. F., Giovannini, M., Le Mouhaer, S., Robeva, A., Waldron-Lynch, M. and Heist, R. S. (2018). Results of the GEOMETRY mono-1 phase II study for evaluation of the MET inhibitor capmatinib (INC280) in patients (pts) with MET Delta ex14 mutated advanced non-small cell lung cancer (NSCLC). Ann. Oncol., 29. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041